Bio Green Med Solution, Inc.
BGMS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BGMS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BGMS
Bio Green Med Solution, Inc. (BGMS) is a clinical-stage biopharmaceutical company focused on developing oncology drug candidates, currently exploring strategic alternatives due to limited liquidity and a going concern uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Bio Green Med Solution, Inc..
Bio Green Med Solution, Inc. (BGMS) is a clinical-stage biopharmaceutical company focused on developing oncology drug candidates, currently exploring strategic alternatives due to limited liquidity and a going concern uncertainty.
- Cash & equivalents of $3.8M as of 2026-06-30 [sec].
- Total revenue of $0.3M and net loss of -$0.4M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of -$2.2M as of 2026-06-30 [sec].
- The company has a history of losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-05-14].
- The Board is considering strategic alternatives including a merger, acquisition, or similar transaction [sec_mda · as of 2026-08-14].
What works
- The company retains worldwide marketing rights to its product candidate Plogo [sec_mda · as of 2025-04-02].
- The Board believes the company could be an attractive candidate for a business combination due to its public listing status [sec_mda · as of 2026-08-14].
- R&D expenses have decreased significantly, with fadraciclib program costs ceasing after liquidation of a subsidiary [news · published 2026-03-30].
What to weigh
- The company does not have sufficient funds to complete development and commercialization of any drug candidates [sec_mda · as of 2025-08-14].
- There is substantial doubt about the company's ability to continue as a going concern within one year [sec_mda · as of 2025-05-14].
- The company has not generated any revenues from product sales to date [sec_mda · as of 2025-04-02].
- Shareholders' equity is negative at -$2.2M as of 2026-06-30 [sec].
From the filings
Quoted directly from source documents.
The company is exploring strategic alternatives including a merger or acquisition.
“the Board believes that it must consider all viable strategic alternatives that are in the best interests of our shareholders. Such strategic alternatives include a merger, acquisition, share exchange, asset purchase, or similar transaction.”
SEC MD&A · August 14, 2026
There is substantial doubt about the company's ability to continue as a going concern.
“our assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”
SEC MD&A · May 14, 2025
The company has not generated any product revenues.
“We have not generated any revenues from product sales to date.”
SEC MD&A · April 2, 2025
The company retains worldwide rights to Plogo.
“We currently retain all marketing rights worldwide to our product candidate Plogo.”
SEC MD&A · April 2, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern within 12 months [sec_mda · as of 2025-05-14].
- Insufficient funding for development — No sufficient funds to complete development and commercialization of any drug candidates [sec_mda · as of 2025-08-14].
- No product revenue — No revenues from product sales to date; depends on future regulatory approvals [sec_mda · as of 2025-04-02].
- Negative shareholders' equity — Shareholders' equity of -$2.2M as of 2026-06-30 indicates financial distress [sec].
What to watch
- Outcome of strategic alternatives review, including potential merger or acquisition [sec_mda · as of 2026-08-14].
- Ability to secure additional funding to continue operations [sec_mda · as of 2025-05-14].
- Progress of Plogo development and any clinical trial updates [sec_mda · as of 2025-04-02].
- Changes in cash position and operating expenses in future filings [sec].
Sources: News · SEC filings · SEC MD&A · Generated August 30, 2026 · How we verify sources →
Run Bio Green Med Solution, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bio Green Med Solution, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
37.9 months
D/E 0.10 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$565
| Holder | Shares | Value |
|---|---|---|
| vsm wealth advisory, llc | 1,882 | $565 |
Governance
Frequently asked questions
What is the AI investment thesis for Bio Green Med Solution, Inc.?
Bio Green Med Solution, Inc. (BGMS) is a clinical-stage biopharmaceutical company focused on developing oncology drug candidates, currently exploring strategic alternatives due to limited liquidity and a going concern uncertainty.
Who is the CEO of Bio Green Med Solution, Inc.?
Dr. Sing Ee Wong is the chief executive officer of Bio Green Med Solution, Inc. (BGMS).
Where is Bio Green Med Solution, Inc. headquartered?
Bio Green Med Solution, Inc. (BGMS) is headquartered in Kuala Lumpur, Malaysia.
What therapeutic areas does Bio Green Med Solution, Inc. focus on?
Bio Green Med Solution, Inc. develops therapies across Neurology, Immunology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.